Moderna shares jump today on positive results in skin cancer vaccine trials
Shares of Moderna (MRNA) were up 13.67% to $89.15 as of noon New York time today, December 14. They closed ahead 9.25% at $85.87. A vaccine developed by Merck and Moderna helped prevent the recurrence of severe skin cancer for three years, according to new results...
Moderna shares popped 3.2% yesterday–here’s why
Shares of Moderna (MRNA) closed up 3.18% yesterday, September 13, on news that 1. The Food & Drug Administration has approved updated Covid-19 vaccine boosters (including one from Moderna) and that the Centers for Disease Control was recommending the boosters for...
Watch my new YouTube video: Trend of the Week Biotech
I’m starting up my videos again–this time using YouTube as a platform. My sixty-sixth YouTube video “Trend of the Week: Biotech” went up today. Please watch and subscribe to my YouTube channel. And like my video. Here’s the...
So what’s the matter with Incyte stock? Just about nothing although you wouldn’t know it from the recent price movement
Shares of biotech stock Incyte (INCY) have been down significantly in 2021. For the year to date, as of the close on March 2, the shares were down 8.45%. In the last month they’ve tumbled 12.42%. So what’s wrong? Pretty much nothing. With the individual...
Nektar should be climbing but this fast?
Nektar (NKTR) is another one of those stocks that looks to be moving up more strongly right now than the relatively sparse news would explain. Shares of this biotech are up 18.96% in the last week and 24.37% for the last 3 months. I can see a stream of positive news...
Ho, Ho, Huh! Is this the shape of this year’s Santa Claus rally to come?
The major indexes aren’t showing much of a move today even on the news that a new coronavirus stimulus/relief bill is like to pass today (along with the massive fiscal 2021 spending bill for the rest of the government.) I think a good part of that lack of...
Adding two pick and shovel buys for the coronavirus vaccine race
The old saw about how to get rich from a gold rush says, Don’t try to strike it rich mining gold; instead sell picks and shovels and blue jeans to the miners. Same still holds in today’s race to produce an effective and safe coronavirus vaccine. One or two...
Incyte beats on earnings, revenue–but drops on lack of improved guidance
Shares of biotech Incyte (INCY) were down 2.60% as of 1:30 p.m. Tuesday on earnings and revenue that stomped Wall Street projections. The company reported second quarter adjusted earnings of $1.24 a share versus Wall Street projections for 50 cents a share. Earnings...
Analyst upgrade is catalyst for 6.17% jump in Acadia Pharmaceuticals today
Stifel analyst Paul Matteis upgraded Acadia Pharmaceuticals (ACAD) to a Buy from a Hold today and raised his target price to $71 from $41. (Shares closed at $57 today, up 6.17%) The upgrade from Matteis was especially powerful since he has been skeptical on the stock...
Raising my target price on Incyte to $120 a share after 58.5% gain in last 3 months
I admit it. I feel silly talking about price targets and valuations in this market. After all everything is just going to the sky. Infinity and Beyond!!! But, as silly as I may feel, I don’t think the gods of investing have repealed the laws of valuation. At...
Stock Pick of the Day: Acadia Pharmaceuticals (ACAD)
As I wrote in my previous post this morning, I like the upward momentum in the biotech sector resulting from the race for a coronavirus vaccine and treatment and the cash flows into the sector from investors and big drug companies such as Pfizer (PFE.) That has pushed...
More headroom for biotech sector–and heads up on a coming pick
On May 29 the iShares NASDAQ Biotechnology ETF (IBB) hit an all-time high of $134.85, breaking the record of $133 set in 2015. Not surprising with money flooding into the sector as everyone and their Aunt Sally looks to find the stock that will rocket to the moon on...
Nektar’s new non-addictive opioid NKTR-181 to finally get an FDA advisory vote tomorrow
I understand why the U.S. Food & Drug Administration has moved so slowly on a decision on Nektar Therapeutic’s (NKTR) new non-addictive opioid NKTR-181. The last thing the FDA wants to do in the midst of epidemic of opioid addiction is to approve a drug...
Nektar’s plunge is a buying opportunity–so I’m adding more to my Volatility Portfolio
What we know about Nektar Therapeutics (NKTR) is pretty clear. On Thursday of last week, August 8, trading in shares of Nektar were halted on news from the company had manufacturing problems that resulted in some patients enrolled in the clinical trials for the...
Nektar Therapeutics bumps along ahead of August FDA action on new non-addictive opioid
Shares of Nektar Therapeutics (NKTR) have been bumping along between $32 and $34 for two months now, but the company continues to take steps to prepare for the likely August approval of NKTR-181, a new non-addictive opioid. Nektar has formed Inheris Biopharma, a...
Making Incyte #9 on my 10 most dangerous stocks for earnings season list–and #5 on my buy on any plunge list
Today on my JubakAM.com subscription site I made Incyte #9 in my 10 Most dangerous Stocks for Earnings Season Special Report–and #5 on my Buy on Any Plunge Bonus Special Report. Here’s what I wrote: “There’s a good chance that Incyte (INCY)...
Updating Nektar ahead of a dangerous earnings season–and looking to add to positions on any plunge
On April 4 I made Nektar Therapeutics (NKTR) #8 in my list of the 10 most dangerous stocks for earnings season and #4 on my list of 5 stock to buy on any plunge in my Special Report on my JubakAm.com subscription site. Here’s what I wrote in that Special...
What a difference a week makes for biotech stocks
Last week the biotech sector seemed in freewill. Bristol Myers Squibb (BMY) had made a deal to buy Celgene (CELG) at a whopping 54% premium to Wednesday’s close and the sector dropped on the news. The prevailing theory was that the deal removed one hungry big...
Incyte knocking on the door of a new upward trend after today’s 6% pop
Reports of results from the December 1-4 meeting of the American Society of Hematology continue to move biotech stocks. Today it was Incyte’s (INCY) turn. The company announced positive results for a Phase 2 trial evaluating Incyte’s Jakafi in combination...
Ionis Pharmaceuticals showing strong recovery on research pipeline, tweaking price target higher
It’s been a wild 2018 for Jubak Picks portfolio stock Ionis Pharmaceuticals (IONS.) Right now, though, the shares are on an upward trend. That’s likely to continue with the company looking at a strong research presentation at the December 1-4 meeting of...
Incyte news continues to rebuild credibility of pipeline
Shares of Incyte  (INCY) climbed 2.51% today on the announcement of positive results from a Phase 2 clinical trial, GEOMETRY mono-1, evaluating MET inhibitor capmatinib in 94 adult patients with advanced non-small cell lung cancer. The company presented the data at...
Why Nektar is extremely oversold right now
The longs and the shorts continue to battle over Nektar Therapeutics (NKTR.) Right now the shorts have the best of that fight. No contest. The shares of this biotech fell another 1.24% today to close at $51.71. A little more than a month ago they were at $68.49. But I...
Nektar beats on earnings–more importantly FDA accepts company’s new opioid for review
I wrote this post while on vacation in an effort to use this down time to catch up on earnings results that I missed during the very busy second quarter earning season. This post was written on August 18. After the market close on Wednesday, August 8,...
Incyte beats on revenue, misses on earnings; reports good progress in pipeline
I am on vacation until August 26. I am using that downtime to catch up on some of the earnings reports I missed during the very busy second quarter earnings season. On July 30 Incyte (INCY) reported second quarter earnings of 26 cents a share, 4 cents below the Wall...
Nektar up 6.32% today on opioid data presentation
Frankly, my holdings of shares and options on Nektar Therapeutics (NKTR) are driving me nuts. The stock is just so volatile that I can barely stand it even though I’m comfortable with the long-term trajectory of the company’s new non-addictive opioid and...
Nektar’s 40% drop yesterday was an extreme over-reaction: What I’m doing now
It’s never good to turn in disappointing results in a drug trial–as Nektar Therapeutics (NKTR) did over the weekend–but to whack 40% off the stock price on this news is an extreme over-reaction. To justify a 40% drop you have to assume 1) that the...
FDA delivers less than half a loaf to INCY and LLY in approving Olumiant
Today the U.S. Food & Drug Administration did finally approve Baricitinib, now known as Olumiant, for the treatment of moderately-to-severely active rheumatoid arthritis. But the approval carries more restrictions than expected. The FDA approved only the 2...
Stock or options, Nektar needs some understanding and patience now
It hasn’t exactly been a stellar couple of months for shares and options on Nektar Therapeutics (NKTR). The stock, which I hold in my Jubak Picks portfolio, is down 23.1% since it hit a high of $108.44 on March 8. The August 17, 2018 call options with a strike...
Positive catalysts are intact for Nektar Therapeutics
Shares of biotech rocket Nektar Therapeutics (NKTR) are down 23.25% since they traded at $106.91 on March 21, 2018. I can’t find evidence that the positive catalysts that led me to recommend the stock for my Jubak Picks portfolio and the options for my...Jim’s Daily Email Alerts:
Every post from Jubak Picks straight to your mailbox. And they're free!